Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14

Benzinga · 3d ago
Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market Perform to Outperform and raises the price target from $7 to $14.